$0.69
5.31% yesterday
Nasdaq, Jun 12, 10:18 pm CET
ISIN
US6963891055
Symbol
PALI
Sector
Industry

Palisade Bio Inc Stock price

$0.69
-0.08 10.27% 1M
-1.67 70.76% 6M
-0.96 58.18% YTD
-3.77 84.53% 1Y
-3,670.86 99.98% 5Y
-2,129,399.31 100.00% 10Y
-2,339,999.31 100.00% 20Y
Nasdaq, Closing price Thu, Jun 12 2025
+0.03 5.31%
ISIN
US6963891055
Symbol
PALI
Sector
Industry

Key metrics

Market capitalization $3.31m
Enterprise Value $-3.92m
EV/FCF (TTM) EV/FCF 0.35
P/B ratio (TTM) P/B ratio 0.57
Free Cash Flow (TTM) Free Cash Flow $-11.35m
Cash position $7.23m
P/E forward negative
Short interest 4.78%

Is Palisade Bio Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,845 stocks worldwide.

Palisade Bio Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

2 Analysts have issued a Palisade Bio Inc forecast:

2x Buy
100%

Analyst Opinions

2 Analysts have issued a Palisade Bio Inc forecast:

Buy
100%

Financial data from Palisade Bio Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 5.80 5.80
6% 6%
-
- Research and Development Expense 9.06 9.06
31% 31%
-
-15 -15
16% 16%
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -15 -15
16% 16%
-
Net Profit -14 -14
17% 17%
-

In millions USD.

Don't miss a Thing! We will send you all news about Palisade Bio Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Palisade Bio Inc Stock News

Neutral
GlobeNewsWire
17 days ago
Study met its primary endpoints of safety, tolerability, and pharmacokinetics (PK)  No serious adverse events (SAEs) or treatment-emergent adverse events (TEAEs) related to laboratory values or EKGs observed across SAD/MAD cohorts Management releases a “What This Means” segment discussing the topline Phase 1a data; Access here Carlsbad, CA, May 27, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (N...
Neutral
GlobeNewsWire
about one month ago
Two posters presented at Digestive Disease Week (DDW) 2025 Preclinical results indicate that PALI-2108 effectively modulates inflammatory pathways in the colon, promoting a favorable immune response Company advancing Phase 1a/b study of PALI-2108 and has demonstrated a favorable safety profile in single-ascending-dose cohorts Carlsbad, CA, May 06, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Na...
Neutral
GlobeNewsWire
about one month ago
Carlsbad, CA, May 01, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade”, “Palisade Bio”, or the “Company”), a clinical-stage biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today announced that it has been selected to give an oral presentation at the 3 rd Annual Precis...
More Palisade Bio Inc News

Company Profile

Palisade Bio, Inc. is a biopharmaceutical company, which engages in the development of oral therapies that help patients with acute and chronic gastrointestinal complications stemming from post-operative digestive enzyme damage. It offers LB1148, an oral formulation of a broad-spectrum serine protease inhibitor designed to neutralize the activity of potent digestive proteases released from the gut during surgery. The company is headquartered in Carlsbad, CA.

Head office United States
CEO J. Finley
Employees 8
Founded 2011
Website palisadebio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today